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Aims Vascular risk factors are associated with cognitive impairment and dementia, although most of the research in this
domain focuses on cerebrovascular factors. We examined the relationship between the recently developed Framing-
ham general cardiovascular risk proﬁle and cognitive function and 10-year decline in late midlife.
Methods
and results
Study sample comprised of 3486 men and 1341 women, mean age 55 years [standard deviation (SD)¼6], from the
Whitehall II study, a longitudinal British cohort study. The Framingham General Cardiovascular Risk proﬁle, assessed
between 1997 and 1999, included age, sex, HDL cholesterol, total cholesterol, systolic blood pressure, smoking
status, and diabetes status. Measures of cognitive function consisted of tests of reasoning (Alice Heim 4-I),
memory, phonemic and semantic ﬂuency, and vocabulary (Mill-Hill), assessed three times (1997–1999, 2002–
2004, 2007–2009) over 10 years. In cross-sectional age-adjusted models, 10% point increments in cardiovascular risk
were associated with poor performance in all cognitive domains in both men and women (all P-values ,0.001). In
models adjusted for age, ethnicity, marital status, and education, 10% higher cardiovascular risk was associated with
greater overall 10-year cognitive decline in men, reasoning in particular (20.47; 95% CI: 20.81, 20.11).
Conclusion In middle-aged individuals free of cardiovascular disease, an adverse cardiovascular risk proﬁle is associated with poor
cognitive function, and decline in at least one cognitive domain in men.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
The importance of vascular risk factors and disease for cognitive
impairment and dementia in older adults is widely recognized.
1–3
There is growing evidence to suggest that these risk factors are
also associated with deﬁcits in cognitive function in midlife, prior
to the onset of overt clinical symptoms of dementia.
4–9 Several
risk algorithms have been developed to predict the risk of stroke
and cardiovascular events.
10–12 Such scores improve the efﬁciency
of risk prediction and provide a more realistic assessment of the
collective importance of risk factors as well as easier interpretation
of the risk of disease. They may equally help identify persons at
increased risk of disease resulting from risk below the clinical
threshold on individual risk factors.
The association between multiple vascular risk factors and cog-
nition has been examined by a number of studies using the Fra-
mingham Stroke Risk Proﬁle (FSRP).
13–16 These studies have
reported an inverse association between the 10-year risk for
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doi:10.1093/eurheartj/ehr133stroke and performance on multiple cognitive tests. The majority
of these studies have used a cross-sectional design, which provides
little information about risk prediction.
14–16 In addition, the FSRP
is designed for prediction of stroke and therefore does not cover
the full range of potentially relevant cardiovascular diseases, such
as myocardial infarction (MI), coronary insufﬁciency, angina, and
peripheral artery disease. We used the recently developed Fra-
mingham General Cardiovascular Disease Risk Proﬁle to examine
associations with cognitive performance and then decline over a
10-year period in a large sample of middle-aged individuals.
Methods
Data were drawn from the Whitehall II study, established in 1985 to
examine the socioeconomic gradient in health and disease among 10
308 civil servants (6895 men and 3413 women). Details of the
cohort have been described previously.
17 Brieﬂy, all London-based
ofﬁce staff aged 35–55 working in 20 civil service departments were
invited to participate, of which 73% agreed. Baseline examination
took place during 1985–1988 and consisted of a clinical examination
and a self-administered questionnaire that included sections on demo-
graphic characteristics, medical history, and health behaviours. Clinical
examination included measures of blood pressure, anthropometry,
biochemical variables, subclinical makers of cardiovascular disease,
and neuroendocrine function. A battery of cognitive tests was intro-
duced to the study at Phase 5 (1997–1999), and repeated at phases
7 (2002–2004) and 9 (2007–2009). Informed consent was obtained
from all participants and the University College London ethics commit-
tee approved the study.
Assessment of risk factors for the
cardiovascular disease risk proﬁle
The Framingham general cardiovascular disease (CVD) risk score is
designed for use in primary care to identify individuals at high risk
for CVD events that include coronary, cerebrovascular and peripheral
arterial disease, and heart failure.
11 Its development was based on the
prediction of 1174 CVD events over a 12-year follow-up period of
8491 participants in the Framingham Heart study. The risk score, cal-
culated using information on age, HDL cholesterol, total cholesterol,
systolic blood pressure, cigarette smoking, and diabetes provides an
estimate of the risk of CVD over a 10-year period.
The risk score components in our study were drawn from question-
naire and clinical examination data at Phase 5. HDL and total choles-
terol (mg/dL) were measured from blood samples collected after
either an 8 h fast for participants presenting in the morning, or at
least 4 h after a light fat-free breakfast for those presenting in the after-
noon. Cholesterol was measured using a Cobas Fara centrifugal analy-
zer (Roche Diagnostics System). HDL cholesterol was measured by
precipitating non-HDL cholesterol with dextran sulfate-magnesium
chloride with the use of a centrifuge and measuring cholesterol in
the supernatant ﬂuid. Systolic blood pressure (mmHg) was taken as
the average of two measurements in the sitting position after a
5 min rest with the Hawksley random-zero sphygmomanometer.
Treated hypertension was determined according to the antihyperten-
sive medication use. This included diuretics, beta-blockers,
ACE-inhibitors, and calcium channel blockers. Participants were cate-
gorized with respect to their cigarette smoking status as current
smokers or past/non-smokers. Diabetes was deﬁned by a fasting
glucose ≥ 7.0 mmol/L or a 2 h post-load glucose ≥11.1 mmol/L or
reported doctor diagnosed diabetes, or use of diabetes medication.
18
Raw scores were calculated and then converted to 10-year risk or
predicted probability of incident CVD expressed as a percentage.
11
Missing data for any risk score component were replaced by data
from Phase 4 (1995–1996), n ¼ 27, and in the case of biological
measures (HDL cholesterol, total cholesterol, and systolic blood
pressure), by data from Phase 3 (1991–1993), n ¼ 624. Individuals
(n ¼ 319) with a history of stroke or coronary heart disease (CHD)
at Phase 5 were excluded. Coronary heart disease status at Phase 5
was deﬁned as non-fatal MI and ‘deﬁnite’ angina. Myocardial infarction
diagnosis, based on clinical examinations at Phases 1, 3, or 5 and
records obtained from general practitioners and hospitals, was
assessed using MONICA criteria.
19 Angina was assessed based on par-
ticipant’s reports of symptoms with corroboration in medical records
or abnormalities on a resting electrocardiogram, an exercise electro-
cardiogram, or a coronary angiogram. Stroke diagnosis was self-
reported and included history of stroke or a transient ischaemic attack.
Cognitive function
The cognitive test battery, administered at the clinical examinations at
Phases 5, 7, and 9, described below, consists of ﬁve standard tasks
chosen to provide a comprehensive assessment of cognitive function.
The Alice Heim 4-I (AH4-I) is composed of a series of 65 verbal and
mathematical reasoning items of increasing difﬁculty.
20 It tests inductive
reasoning, measuring the ability to identify patterns and infer principles
and rules. The time allowed for this test was 10 min.
Short-term verbal memory was assessed with a 20-word free recall
test. Participants were presented a list of 20 one or two syllable words
at two second intervals and were then asked to recall in writing as
many of the words in any order and had 2 min to do so.
We used two measures of verbal ﬂuency: phonemic and semantic.
Phonemic ﬂuency was assessed via ‘S’ words and semantic ﬂuency
via ‘animal’ words.
21 Subjects were asked to recall in writing as many
words beginning with ‘S’ and as many animal names as they could.
One minute was allowed for each test.
Vocabulary was assessed using the Mill Hill Vocabulary test, used in its
multiple-choice format, consisting of a list of 33 stimulus words
ordered by increasing difﬁculty and six response choices.
22
Covariates
The following covariates were included; age, marital status, ethnicity,
and education. Although age is a component of the Framingham
General CVD risk score, we included it as a covariate because of its
established association with cognitive function.
23 Ethnicity consisted
of two groups; white and non-white. Marital status included two cat-
egories; married/cohabiting and single/divorced/widowed. Education
was measured as the highest level of education achieved. Categories
included (i) elementary or lower secondary, (ii) higher secondary
(A’ levels), and (iii) ﬁrst university degree or higher. We also examined
the effect of occupational position at baseline in lieu of education. This
variable consisted of three categories: (i) high (administrative), (ii)
intermediate (professional or executive), and (iii) low (clerical or
support).
Statistical methods
Descriptive analyses were carried out to examine the distribution of
the CVD risk score components, all covariates, as well as cognitive
function, and decline in our study population. In order to carry out
cross-sectional and longitudinal analyses on the same population, we
started with those who had data at Phase 5 and at least one repeat
measure so that cognitive decline could be calculated (implying partici-
pation in Phase 7 or 9 of the study). Approximately 86% of the 4837
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of this study. As follow-up time varied between individuals (mean ¼
10.5, SD ¼ 0.5), we ﬁrst estimated the rate of change, standardizing
it to represent 10-year change for each individual. The interaction
term between the risk score and sex (P , 0.001 for all cognitive
tests) led us to stratify all analyses by sex.
We ﬁrst explored correlations of the 10-year CVD risk, assessed at
Phase 5, with cognitive function at Phases 5 and 9 and cognitive decline
over the 10-year follow-up. Subsequently, regression analysis was used
to model the impact of a 10% increment in CVD risk on cognitive func-
tion at Phase 5 and 10-year cognitive decline. In these analyses, we ﬁrst
calculated an overall test of association using multivariate analysis of
variance (MANOVA) in order to account for the correlation
between the cognitive tests and control type 1 error inﬂation due to
multiple tests. Then, linear regression was used to determine the
cross-sectional association between the CVD risk, modelled to show
the impact of a 10% point increment in risk, and each cognitive test
separately. We ﬁrst examined unadjusted models, followed by
models adjusted for age only, and ﬁnally the fully adjusted models
including all four covariates.
The longitudinal analyses assessed the association between 10-year
CVD risk at Phase 5 and 10-year cognitive decline, calculated using
data from Phases 5, 7, and 9 as described earlier. Linear regression
was used to model the association between a 10% increment in
CVD risk at baseline and cognitive decline. The adjustment for cov-
ariates was performed in three steps, as in the cross-sectional analy-
sis. MANOVA analyses were also carried out to examine the
association between CVD risk and overall cognitive decline. In sup-
plementary analyses, occupational position replaced adjustment for
education in order to assess the effect of a later life measure of
socioeconomic circumstances. Tests of statistical signiﬁcance were
two sided and results were statistically signiﬁcant at P , 0.05. All ana-
lyses were conducted using SAS software (version 9; SAS Institute,
Cary, NC).
Results
Of 10 308 participants at baseline of the Whitehall II study (Phase 1,
1985–1988), 7830 (75.9%) individuals at Phase 5 (1997–1999)
responded to the questionnaire or came to the clinical examination.
Of these,5146(65.7%)had complete dataon cognitivefunction and
allcovariates.Afterexcluding319participantswithahistoryofCHD
orstrokeatPhase5,ourﬁnalstudysampleconsistedof4827individ-
uals (3486 men and 1341 women). Compared with the sample used
inthisanalysis,participantsatPhase5excludedfromthisstudyhada
higher mean 10-year CVD risk (12.1 vs. 9.8%, P , 0.001). Missing
data were also inﬂuenced by age, sex, and education as individuals
excluded were more likely to be women, older, and have a lower
level of education (all P-values , 0.001).
The characteristics of the study population are shown in Table 1.
Men had a considerably higher mean 10-year CVD risk than
women; 1711 (49.1%) and 514 (14.7%) of men and 71 (5.3%)
and 3 (0.2%) of women had a 10-year CVD risk higher than 10
and 20%, respectively. The correlation analysis (see Supplementary
material online, Table S1) suggested robust cross-section and pro-
spective associations between CVD risk and cognition except the
association with vocabulary at Phase 5 in men. These associations
were largely similar in men and women, except for the tests of
reasoning and vocabulary.
Regression analysis to model the cross-sectional associations
between 10% increment in Framingham CVD risk and cognitive
function are presented in Table 2. The MANOVA analyses show
signiﬁcant associations between the CVD risk and overall cognitive
function in the fully adjusted model in men (P ¼ 0.05) and women
(P , 0.03). The unadjusted regression estimates show a 10%
higher CVD risk to be associated with 1.66 lower score on the
test of reasoning (AH4-I) for men [95% conﬁdence interval
(CI) ¼ 22.10, 21.22]. In the unadjusted models, CVD risk was
inversely associated with all individual cognitive domains except
the vocabulary test in men (P ¼ 0.30). These associations were
robust to adjustment for age (all P-values , 0.01). In the fully
adjusted models, all tests except reasoning in men (P ¼ 0.17)
and the verbal ﬂuency tests in women remained associated with
CVD risk. Adjustment for occupational position yielded similar
results to analyses adjusted for education (see Supplementary
material online, Table S2).
Table 3 shows the results of linear regression used to model the
relation between a 10% increment in CVD risk at baseline and cog-
nitive decline over 10 years. The unadjusted MANOVA (P ,
0.001) suggests an association between CVD risk and overall cog-
nitive decline only in men. In unadjusted models, a 10% increment
in CVD risk was associated with 1.30 points (95% CI ¼ 21.58,
21.02) greater decline in reasoning. In unadjusted models in
men, these affects were evident for all cognitive domains except
memory; in fully adjusted models, the association was robust
only with reasoning (P ¼ 0.009). Replacing education with occu-
pational position did not lead to signiﬁcant changes in the results
(see Supplementary material online, Table S3).
The results on cognitive decline in women prompted us to
further explore this association by categorizing the risk score dif-
ferently in men and women (see Supplementary material online,
Table S4). These results, adjusted for all covariates, suggest that
all cognitive domains except vocabulary decline in all CVD risk
groups in men and women.
We carried out several sensitivity analyses to test the robustness
of our ﬁndings. First, we examined whether use of antihypertensive
medication, a component of the Framingham CVD risk algorithm,
over the follow-up period, from Phase 5 to Phase 9, affected the
association between CVD risk and cognitive decline. An increasing
proportion of participants in the study reported to be on antihy-
pertensive medication, 9.0% at Phase 5, 20.3% at Phase 7, 23.3%
at Phase 8, and 31.3% at Phase 9. As expected, adjustment for
use of antihypertensive medication over study follow-up slightly
attenuated the association between CVD risk and cognitive
decline in both men and women. We obtained similar results
when we adjusted for use of other classes of CVD medications
(nitrates, antiplatelets, and lipid lowering drugs); results not
shown but available upon request.
Second, we repeated the analyses of the association between
CVDriskandcognitivedecline,excludingparticipantswhohadavali-
dated CHD event over the follow-up (n ¼ 160). These results were
essentially the same as those reported in the main analyses.
Third, since we had imputed the Framingham CVD risk
proﬁle for participants who were missing data for one or more
components of the risk score, we repeated all analyses with
the sample of participants who had complete data at Phase 5
S. Kaffashian et al. 2328(n ¼ 4221). Again, we observed similar results to those in the
analyses with the imputed data.
Discussion
In this large prospective cohort study of a middle-aged popu-
lation, an adverse Framingham general CVD risk proﬁle, a vali-
dated predictor of future CVD, was associated with poor
cognitive function in middle-aged men and women. When
these associations were modelled using 10% increment in CVD
risk, as has been previously done for stroke risk,
14,15 the effects
were much larger for women than for men. This may be due
to the differences in risk distribution in men and women; in
our study, and perhaps in others, the mean CVD risk in
women was lower, at 4.1% compared with 12% in men. In our
study, cross-sectional correlation coefﬁcients (see Supplementary
material online, Table S1) between CVD risk and cognitive func-
tion pointed to comparable associations in men and women.
Thus, a 10% increase in CVD risk is a considerably larger increase
in risk in women compared with men. In regression analyses,
cross-sectional associations were robust and largely persisted
after adjustment for demographic variables and education. With
respect to 10-year cognitive decline, there was evidence of cog-
nitive decline in all domains except vocabulary at all levels of
CVD risk. However, higher CVD risk was associated with
greater decline only in reasoning in men.
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Table 1 Characteristics of the study population
Variables Men (n 5 3486) Women (n 5 1341) P-value
†
Framingham general cardiovascular disease risk proﬁle (%) 12.0 (7.1) 4.1 (2.8) ,0.001
General cardiovascular disease risk score components
Mean age (years) 55.1 (5.9) 55.3 (5.9) 0.24
Mean HDL (mg/dL) 53.0 (13.2) 65.0 (16.6) ,0.001
Mean total serum cholesterol (mg/dL) 227.5 (39.1) 230.9 (41.3) 0.008
Mean untreated systolic blood pressure (mmHg) 122.4 (15.5) 119.6 (16.7) ,0.001
Mean treated systolic blood pressure (mmHg) 131.6 (15.3) 129.2 (15.7) 0.12
Current smoker (%) 7.9 10.4 ,0.001
History of diabetes (%) 3.8 3.4 0.52
Covariates
Marital status (%)
Married/cohabiting 83.9 60.2 ,0.001
Single/widowed/divorced 16.1 39.7
Ethnicity (%)
White 94.3 87.9 ,0.001
Non-white 5.6 12.1
Education (%)
Lower primary/secondary 37.4 53.2 ,0.001
A levels 28.1 23.0
University 34.5 23.8
Cognitive test raw scores at Phase 5
Reasoning (AH4-I, range, 0–65) 49.2 (9.5) 42.9 (11.6) ,0.001
Memory (range, 0–20) 6.9 (2.3) 7.1 (2.7) 0.12
Semantic ﬂuency (range, 0–35) 16.8 (3.9) 16.2 (4.5) ,0.001
Phonemic ﬂuency (range, 0–35) 17.1 (4.2) 16.9 (4.6) 0.31
Vocabulary (Mill Hill, range, 0–33) 25.8 (3.6) 23.6 (5.2) ,0.001
10-year cognitive decline
a
Reasoning (AH4-I, range, 0–65) 23.6 (6.1) 23.8 (6.3) 0.47
Memory (range, 0–20) 20.6 (2.5) 20.5 (3.2) 0.24
Semantic ﬂuency (range, 0–35) 21.5 (3.4) 21.2 (3.5) 0.03
Phonemic ﬂuency (range, 0–35) 21.7 (3.6) 21.7 (4.0) 0.98
Vocabulary (Mill Hill, range, 0–33) 20.02 (2.1) 0.2 (2.3) 0.003
Values are mean (SD) where appropriate.
aDecline calculated using three repeat measures Phases 5 (1997–1999), 7 (2002–2004), and 9 (2007–2009) and standardized to represent 10-year decline in order to take into
account variations in the follow-up.
†P-value for mean difference between men and women.
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Findings from this study support results from studies that have
examined the importance of multiple vascular and cardiovascular
risk factors by examining the collective effect of individual risk
factors in relation to cognition.
24–28 For example, Whitmer
et al.
28 reported that the presence of multiple cardiovascular risk
factors at midlife independent of age, race, sex, and education sub-
stantially increased risk of dementia in old age. Those having
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Table 3 The association between a 10% increment in the Framingham 10-year cardiovascular disease risk and cognitive
decline
a
Cognitive domain Unadjusted Adjusted for age Multiple adjusted
b
b
c 95% CI P-value b
c 95% CI P-value b
c 95% CI P-value
Men
MANOVA ,0.001 0.04 0.04
Reasoning (AH 4-I) 21.30 21.58, 21.02 ,0.001 20.46 20.81, 20.10 0.01 20.47 20.82, 20.11 0.009
Memory 20.05 20.16, 0.07 0.45 0.08 20.06, 0.23 0.28 0.06 20.09, 0.21 0.43
Semantic ﬂuency 20.27 20.43, 20.11 ,0.001 20.13 20.33, 0.07 0.20 20.15 20.35, 0.04 0.14
Phonemic ﬂuency 20.17 20.34, 0.00 0.05 20.14 20.36, 0.07 0.19 20.16 20.38, 0.05 0.14
Vocabulary (Mill Hill) 20.25 20.35, 20.15 ,0.001 20.09 20.22, 0.03 0.14 20.08 20.21, 0.04 0.17
Women
MANOVA 0.13 0.14 0.04
Reasoning (AH4-I) 20.06 21.28, 1.16 0.92 1.09 20.16, 2.34 0.08 1.17 20.08, 2.44 0.07
Memory 20.33 20.94, 0.28 0.29 20.19 20.82, 0.44 0.55 20.27 20.91, 0.36 0.39
Semantic ﬂuency 20.56 21.22, 0.10 0.09 20.48 21.16, 0.21 0.17 20.67 21.36, 0.02 0.06
Phonemic ﬂuency 20.29 21.06, 0.48 0.46 20.15 0.94, 0.65 0.72 20.08 20.89, 0.72 0.83
Vocabulary (Mill Hill) 20.51 20.95, 20.06 0.03 20.39 20.85, 0.08 0.10 20.42 20.89, 0.04 0.07
aDecline calculated using three repeat measures Phases 5 (1997–1999), 7 (2002–2004), and 9 (2007–2009) and standardized to represent 10-year decline in order to take into
account variations in the follow-up.
bAdjusted for age, ethnicity, marital status, education.
cb represents the regression coefﬁcient showing the impact of a 10% increase in cardiovascular disease risk.
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Table 2 Cross-sectional association between a 10% increment in the Framingham 10-year cardiovascular disease risk
and cognitive function
Unadjusted Adjusted for age Multiple adjusted
a Cognitive domain
b
b 95% CI P-value b
b 95% CI P-value b
b 95% CI P-value
Men
MANOVA ,0.001 ,0.001 0.05
Reasoning (AH 4-I) 21.66 22.10, 21.22 ,0.001 20.93 21.49, 20.37 0.001 20.34 20.82, 0.14 0.17
Memory 20.56 20.66, 20.45 ,0.001 20.20 20.33, 20.06 0.003 20.14 20.27, 20.01 0.04
Semantic ﬂuency 20.85 21.03, 20.67 ,0.001 20.40 20.63, 20.17 ,0.001 20.24 20.45, 20.02 0.03
Phonemic ﬂuency 20.88 21.08, 20.69 ,0.001 20.40 20.64, 20.15 0.001 20.25 20.48, 20.01 0.04
Vocabulary (Mill Hill) 20.09 20.26, 0.08 0.30 20.46 20.66, 20.24 ,0.001 20.23 20.42, 20.05 0.01
Women
MANOVA ,0.001 ,0.001 0.03
Reasoning (AH4-I) 28.74 210.91, 26.58 ,0.001 25.60 27.78, 23.43 ,0.001 22.65 24.42, 20.87 0.003
Memory 21.41 21.92, 20.91 ,0.001 20.92 21.44, 0.39 ,0.001 20.58 21.08, 20.07 0.03
Semantic ﬂuency 22.57 23.43, 21.72 ,0.001 21.33 22.19, 20.47 0.002 20.33 21.08, 0.42 0.38
Phonemic ﬂuency 22.24 23.12, 21.36 ,0.001 21.25 22.15, 20.35 0.006 20.62 21.48, 0.23 0.15
Vocabulary (Mill Hill) 22.96 23.94, 21.98 ,0.001 22.28 23.29, 21.27 ,0.001 20.81 21.60, 20.02 0.05
aAdjusted for age, ethnicity, marital status, education.
bb represents the regression coefﬁcient showing the impact of a 10% increase in cardiovascular disease risk.
S. Kaffashian et al. 2330simultaneously high cholesterol, hypertension, diabetes, and being
smokers had more than a two-fold greater risk of dementia than
those with no such risk factors. The dementia risk score developed
by Kivipelto et al.
24 also highlights the role of multiple cardiovascu-
lar risk factors in middle age and the future risk of dementia.
Given the importance of multiple vascular risk factors in relation
to cognitive function, stroke, and CHD, the more global CVD
risk scores present an important opportunity to study these
associations. Although most of the studies in this domain have
focused on stroke risk scores, especially the FSRP,
13–16 we can
draw some comparisons with these investigations. The cross-
sectional associations between CVD risk and cognitive function,
observed in our study, are largely consistent with results obtained
in these studies. However, comparison with their ﬁndings is limited
because of differences in study populations and neuropsychological
tests used. In addition, whereas we found sex differences in the
associations and stratiﬁed our analyses accordingly, none of these
studies reported sex differences in the association between
stroke risk and cognitive function. We found that after adjusting
for age, sex, and education, 10-year CVD risk was associated
with poorer performance in the test of memory in both men
and women. However, while one study found an association
with stroke risk and memory,
15 the other two did not ﬁnd a
similar association.
14,16
Our results concerning the association between CVD risk and
10-year cognitive decline suggest a similar rate of decline at all
levels of risk in women. In men, there is an indication of a global
effect that in individual tests show greater decline in inductive
reasoning in those with higher CVD risk at baseline. A previous
study on older men showed the Framingham stroke risk score
to predict decline in verbal ﬂuency but not memory and visuospa-
tial performance.
13 Knopman et al.
5 reported a steeper 6-year
decline in processing speed and phonemic ﬂuency in diabetics
and only in processing speed for individuals with hypertension.
Another study in an older cohort found an association between
hypertension and cognitive decline over a 4-year period.
29 Our
ﬁnding for no greater decline in memory in those with higher
CVD risk is consistent with a body of literature suggesting that
frontally mediated cognitive functions, such as verbal ﬂuency,
may be more vulnerable to the pathophysiological processes
linked to cardiovascular risk factors than other cognitive abilities
such as memory.
5,30,31
Strengths and limitations
There are a number of limitations to our study. First, the partici-
pants of the Whitehall II study are ofﬁce-based civil servants and
thus are not fully representative of the British population which
may limit the generalizability of our ﬁndings. Second, individuals
who were included in our analysis had a more favourable demo-
graphic and CVD risk proﬁle, suggesting that our results may be
an underestimation of the relationship between CVD risk and cog-
nitive function. In addition, since participants were tested three
times over 10 years, there is a possibility of practice effects.
32 As
a result, the observed decline in cognitive function may again be
an underestimation of the true extent of longitudinal cognitive
decline. Finally, the relatively low 10-year CVD risk for women
in our study population did not allow adequate examination of
the relation between CVD risk and 10-year cognitive decline in
women.
Conclusions and implications
In summary, our study is the ﬁrst to examine the relationship
between CVD risk as determined by the Framingham general
CVD risk proﬁle, and cognitive function and 10-year decline in a
large middle-aged cohort. Our results are important as they
suggest that not only adverse CVD risk is robustly related to
poorer cognitive function in late midlife, it is also associated with
decline in at least one cognitive domain in men. To make a differ-
ence in outcomes, current thinking about cognitive ageing must
shift from focusing on thresholds to a continuum of cognitive
impairment.
33 Moreover, the current emphasis on risk factors
especially treatable ones such as vascular risk factors must shift
from late to early stages; subtle cognitive changes have been
shown to be present as early as 22 years before diagnosis of Alz-
heimer’s disease.
34 Our own analyses concerning the role of treat-
ment with antihypertensive medications in attenuating the
association between CVD risk and cognitive decline suggest that
early preventive measures and treatment of CVD risk factors
may indeed have a positive impact on cognitive outcomes. The Fra-
mingham CVD risk score presents a convenient way to identify
individuals at an increased risk of cognitive deﬁcits later in life.
Given the ageing of populations worldwide and the link between
impaired cognitive function in midlife and dementia, early targeting
and treatment of cardiovascular risk factors, already important in
their own right, should gain urgency for prevention of cognitive
impairment in late life.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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